Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and Mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380492/
https://www.ncbi.nlm.nih.gov/pubmed/28138853
http://dx.doi.org/10.1007/s13300-017-0229-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380492/
https://www.ncbi.nlm.nih.gov/pubmed/28138853
http://dx.doi.org/10.1007/s13300-017-0229-8

Ejemplares similares